News & Public Events

Paidion Research Names Roberson VP of Clinical Operations

(RESEARCH TRIANGLE PARK, NC) Paidion Research, Inc., a new clinical research organization (CRO) focused exclusively on pediatrics and specializing in NICU and PICU populations (neonatal and pediatric intensive care), recently named Destrey Roberson Vice President of Clinical Operations. He brings significant NICU experience to Paidion including leadership of two of the largest, interventional NICU trials conducted (one with 1550 neonates in 92 NICUs in six countries and another with 200 neonates in 100 NICUs in two countries).

In addition, Roberson will use his international expertise in biologics, pharmaceuticals, medical devices and diagnostic imaging in all aspects of human trials (Phase I-IV, IDE, HDE, post market) to help the company provide its drug and device development partners comprehensive global services such as pharmacometrics, innovative regulatory strategies and efficient, effective global trial execution.

At Paidion, Roberson will be responsible for operational strategy and excellence; cross-functional oversight of trials development, execution and management; and client relationships. He has more than two decades in the patient care and clinical research fields at start-ups, CROs and Fortune 100 companies including InVentiv Health Clinical, Quintiles and Biosynexus. In addition to pediatrics, his experience covers a wide range of therapeutic areas: immunotherapy/infectious disease, cardiology, obstetrics/gynecology, hematology, rheumatology, endocrinology, dermatology, virology, hepatology (hepatic encephalopathy and diagnostic imaging), pulmonology and oncology (diagnostic imaging).

Paidion Research, Inc is a clinical research organization (CRO) focused solely on pediatrics and specializing in NICU and PICU populations (neonatal and pediatric intensive care). Headquartered in Durham, NC, they combine pediatric clinical pharmacology expertise with innovative pediatric regulatory strategies and trial methodologies to provide best-in-class service to drug and device development partners in industry, government, academia and nonprofits. For more about the company, visit their recently launched website or email